One of the presenters at the JPMorgan conference yesterday was the biotech Dendreon (NASDAQ:DNDN), a stock that gets a lot of attention from readers of Fool.com. In this video, Motley Fool health care bureau chief Brenton Flynn discusses three bullish points from the company's presentation. He gives us areas where the company is growing, tells us how it is increasing awareness around its treatment -- which may buoy all players in that sector -- and talks about some progress that the company has made in its restructuring efforts.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
